Securities Registration: Employee Benefit Plan (s-8)
May 18 2021 - 5:02AM
Edgar (US Regulatory)
As
filed with the Securities and Exchange Commission on May 17, 2021
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-8
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
VYANT
BIO, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
04-3462475
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(I.R.S.
Employer
Identification
No.)
|
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(Address
of Principal Executive Offices) (Zip Code)
Vyant
Bio, Inc. 2021 Equity Incentive Plan
StemoniX,
Inc. 2015 Stock Option Plan
(Full
title of the plan)
John
A. Roberts
President
and Chief Executive Officer
Vyant
Bio, Inc.
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(201)
479-8126
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Please
send copies of all communications to:
Alan
Wovsaniker, Esq.
Lowenstein
Sandler LLP
One
Lowenstein Drive
Roseland,
New Jersey 07068
Tel:
973-597-2500
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large
accelerated filer
|
[ ]
|
|
Accelerated
filer
|
[ ]
|
|
|
|
|
|
Non-accelerated
filer
|
[X]
|
|
Smaller
reporting company
|
[X]
|
|
|
|
|
|
|
|
|
Emerging
growth company
|
[ ]
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. [ ]
CALCULATION
OF REGISTRATION FEE
Title of Securities
To Be Registered
|
|
Amount To Be Registered(1)
|
|
|
Proposed
Maximum
Offering Price
Per Share
|
|
|
Proposed
Maximum Aggregate Offering Price
|
|
|
Amount of
Registration
Fee
|
|
Common Stock, par value $0.0001 per share, reserved for issuance pursuant to the Vyant Bio, Inc. 2021 Equity Incentive Plan
|
|
|
4,500,000
|
|
|
$
|
2.98
|
(2)
|
|
$
|
13,410,000
|
|
|
$
|
1,463.04
|
|
Common Stock, par value $0.0001 per share, reserved for issuance pursuant to stock option awards outstanding under the StemoniX, Inc. 2015 Stock Option Plan, as amended
|
|
|
891,780
|
|
|
$
|
1.46
|
(3)
|
|
$
|
1,301,999
|
|
|
$
|
142.05
|
|
Total
|
|
|
5,391,780
|
|
|
$
|
|
|
|
$
|
14,711,999
|
|
|
$
|
1,605.09
|
|
(1)
|
This
Registration Statement on Form S-8 (the “Registration Statement”) covers shares of Common Stock, par value $0.0001 per
share (“Common Stock”), of Vyant Bio, Inc. (the “Company” or the “Registrant”) issuable pursuant
to the Vyant Bio, Inc. 2021 Equity Incentive Plan (the “2021 Plan”) and the StemoniX, Inc. 2015 Stock Option Plan (the
“2015 Plan” and, together with the 2021 Plan, the “Plans”) and, pursuant to Rule 416(a) under the Securities
Act of 1933, as amended (the “Securities Act”), any additional securities as may become issuable pursuant to the adjustment
provisions of the Plans.
|
|
|
(2)
|
Pursuant
to Rule 457(c) and Rule 457(h) under the Securities Act, the proposed maximum offering price per share and the proposed maximum aggregate
offering price are estimated for the purpose of calculating the amount of the registration fee and are based on the average of the
high and low sales price on the NASDAQ Capital Market on May 11, 2021.
|
|
|
(3)
|
Estimated
pursuant to Rule 457(h) and Rule 457(c) under the Securities Act, solely for the purpose of computing the registration fee, based
on the weighted average exercise price of the stock options outstanding under the 2015 Plan.
|
EXPLANATORY
NOTE
On
March 30, 2021 (the “Effective Date”), Vyant Bio, Inc., formerly known as Cancer Genetics, Inc. (the “Company”
or the “Registrant”), completed its business combination with StemoniX, Inc., a Minnesota corporation (“StemoniX”),
in accordance with the Agreement and Plan of Merger and Reorganization, dated as of August 21, 2020, as amended (the “Merger Agreement”)
by and among the Company, StemoniX and CGI Acquisition, Inc., a Minnesota corporation and wholly-owned subsidiary of the Company (“Merger
Sub”), pursuant to which Merger Sub merged with and into StemoniX, with StemoniX surviving the merger as a wholly-owned subsidiary
of the Company (the “Merger”).
As
of the Effective Date, pursuant to the Merger Agreement, the Company assumed the StemoniX, Inc. 2015 Stock Option Plan (the “2015
Plan”) and issued options (the “Replacement Options”) to purchase an aggregate of 891,780 shares of common stock of
the Registrant, par value $0.0001 per share (the “Common Stock”), with a weighted average exercise price of $1.46 per share,
in exchange for StemoniX options that were granted by StemoniX prior to the Merger pursuant to the 2015 Plan. This Registration Statement
relates to the registration of 891,780 shares of Common Stock issuable upon exercise of the Replacement Options under the 2015 Plan.
PART
I
Information
Required in the Section 10(a) Prospectus
Item
1. Plan Information.
The
information called for by Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”)
and has been or will be sent or given to participating service providers in accordance with Rule 428 of the Securities Act of 1933, as
amended (the “Securities Act”), and the instructions to Form S-8. In accordance with the rules and regulations of the Securities
and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the
Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the
Securities Act.
Item
2. Registrant Information and Employee Plan Annual Information.
Vyant
Bio, Inc. (the “Company”) will furnish without charge to each person to whom the prospectus is delivered, upon the written
or oral request of such person, a copy of any and all of the documents incorporated by reference into this Registration Statement pursuant
to Item 3 of Part II hereof, other than exhibits to such documents (unless such exhibits are specifically incorporated by reference in
such documents that are incorporated), and the other documents required to be delivered to eligible participants in the Plan pursuant
to Rule 428(b) under the Securities Act. Those documents are incorporated by reference in the Section 10(a) prospectus. Requests should
be directed to:
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
Attention:
Chief Financial Officer
Telephone:
(201) 479-8126
PART
II
Information
Required in the Registration Statement
Item
3. Incorporation of Documents by Reference.
The
following documents filed by the Company with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), are incorporated herein by reference:
|
(a)
|
the
Company’s annual report on Form 10-K filed pursuant to Section 13(a) or 15(d) of the Exchange Act for the fiscal year ended
December 31, 2020, filed with the Commission on March 31, 2021;
|
|
|
|
|
(b)
|
the
Company’s quarterly report on Form 10-Q filed pursuant to Section 13(a) or 15(d) of
the Exchange Act for the fiscal quarter ended March 31, 2021, filed with the Commission on
May 17, 2021;
|
|
(c)
|
the
Company’s current reports on Form 8-K filed with the Commission on January 7, 2021, January 28, 2021, February 1, 2021, February
8, 2021, February 16, 2021, February 26, 2021, March 16, 2021, March 25, 2021 and April 5, 2021 (other than any portions thereof
deemed furnished and not filed); and
|
|
(d)
|
the
description of our common stock, par value $0.0001 per share, contained in our Form 8-A filed on August 12, 2013, including any amendment
or report filed for the purpose of updating such description.
|
All
documents filed by the Company pursuant to Section 13(a), 13(c), 14, or 15(d) of the Exchange Act subsequent to the filing of this Registration
Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or
which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement
and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or
superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which
also is deemed to be incorporated by reference herein, modifies or supersedes such statement.
Item
4. Description of Securities.
Not
applicable.
Item
5. Interests of Named Experts and Counsel.
Not
applicable.
Item
6. Indemnification of Directors and Officers.
We
are incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law authorizes a court to award,
or a corporation’s board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such
indemnification under certain circumstances for liabilities, including reimbursement for expenses incurred, arising under the Securities
Act of 1933, as amended, or the Securities Act.
Our
fourth amended and restated certificate of incorporation provides for indemnification of our directors and executive officers to the
maximum extent permitted by the Delaware General Corporation Law, and our amended and restated bylaws provide for indemnification of
our directors and executive officers to the maximum extent permitted by the Delaware General Corporation Law.
In
addition, we have entered into indemnification agreements with each of our current directors and executive officers. These agreements
will require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise
by reason of their service to us and to advance expenses incurred as a result of any proceeding against them as to which they could be
indemnified. We also intend to enter into indemnification agreements with our future directors and executive officers.
Except
as set forth elsewhere in this prospectus, there is no pending litigation or proceeding involving any of our directors or executive officers
as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result
in a claim for indemnification.
We
have an insurance policy covering our officers and directors with respect to certain liabilities, including liabilities arising under
the Securities Act.
Insofar
as indemnification for liabilities arising under the Securities Act, may be permitted to directors, officers and controlling persons
of the Registrant, the Registrant has been advised that, in the opinion of the Commission, such indemnification is against public policy
as expressed in the Securities Act, and is, therefore, unenforceable.
Item
7. Exemption from Registration Claimed.
Not
applicable.
Item
8. Exhibits.
For
a list of exhibits, see the Exhibit Index in this Registration Statement, which is incorporated into this Item by reference.
Item
9. Undertakings.
(a)
|
The
undersigned Registrant hereby undertakes:
|
(1)
to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration
Fee” table in the effective registration statement; and
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.
Provided,
however, that Paragraphs (a)(1)(i) and (a)(1)(ii) of this section shall not apply if the information required to be included in a
post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant
to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in
the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof:
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(b)
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing
of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where
applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer, or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.
EXHIBIT
INDEX
INDEX
TO EXHIBITS
Exhibit
No.
|
|
Description
|
4.1
|
|
Fourth Amended and Restated Certificate of Incorporation of Cancer Genetics, Inc., filed as Exhibit 3.1 to Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 15, 2013 and incorporated herein by reference.
|
|
|
|
4.2
|
|
Amendment to Certificate of Incorporation of the Company related to the Name Change (incorporated herein by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the SEC on April 5, 2021).
|
|
|
|
4.3
|
|
Amended and Restated Bylaws of Cancer Genetics, Inc., filed as Exhibit 3.4 to Form S-1/A filed on April 30, 2012 (File No. 333-178836) and incorporated herein by reference.
|
|
|
|
4.4
|
|
Specimen Common Stock certificate of Cancer Genetics, Inc., filed as Exhibit 4.1 to Form S-1/A filed on May 16, 2012 (File No. 333-178836) and incorporated herein by reference.
|
|
|
|
5.1
|
|
Opinion of Lowenstein Sandler LLP.*
|
|
|
|
23.1
|
|
Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.*
|
|
|
|
23.2
|
|
Consent of Marcum LLP, Independent Registered Public Accounting Firm.*
|
|
|
|
23.3
|
|
Consent of Lowenstein Sandler LLP (included in Exhibit 5.1).*
|
|
|
|
24.1
|
|
Power of Attorney (included on the signature page).*
|
|
|
|
99.1
|
|
Vyant Bio, Inc. 2021 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on April 5, 2021).
|
|
|
|
99.2
|
|
StemoniX, Inc. 2015 Stock Option Plan, as amended.*
|
|
|
|
*
Filed herewith.
|
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in Cherry Hill, New Jersey, on May 17, 2021.
|
VYANT
BIO, INC.
|
|
|
|
|
By:
|
/s/
John A. Roberts
|
|
|
John
A. Roberts
|
|
|
President
and Chief Executive Officer
|
POWER
OF ATTORNEY AND SIGNATURES
KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John A. Roberts and Andrew D.
C. LaFrence and each of them, each with full power to act without the other, his true and lawful attorneys-in-fact and agents, each with
full power of substitution and resubstitution, for such person and in his name, place and stead, in any and all capacities, to sign any
amendments to this registration statement, and to sign any registration statement for the same offering covered by this registration
statement, including post-effective amendments or registration statements filed pursuant to Rule 462(b) under the Securities Act of 1933,
and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
hereby ratifying and confirming that each of said such attorneys-in-fact and agents or his substitute or substitutes, may do or cause
to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on
behalf of the registrant in the capacities and on the dates indicated.
Person
|
|
Capacity
|
|
Date
|
|
|
|
|
|
/s/
John A. Roberts
|
|
President,
Chief Executive Officer and Director
|
|
May
17, 2021
|
John
A. Roberts
|
|
(Principal
Executive Officer)
|
|
|
|
|
|
|
|
/s/
Andrew D.C. LaFrence
|
|
Chief
Financial Officer
|
|
May
17, 2021
|
Andrew
D.C. LaFrence
|
|
(Principal
Financial and Accounting Officer
|
|
|
|
|
|
|
|
/s/
John Fletcher
|
|
Chairman
|
|
May
17, 2021
|
John
Fletcher
|
|
|
|
|
|
|
|
|
|
/s/
Yung-Ping Yeh
|
|
Chief
Innovation Officer and Director
|
|
May
17, 2021
|
Yung-Ping
Yeh
|
|
|
|
|
|
|
|
|
|
/s/
Marcus Boehm
|
|
Director
|
|
May
17, 2021
|
Marcus
Boehm
|
|
|
|
|
|
|
|
|
|
/s/
Paul Hansen
|
|
Director
|
|
May
17, 2021
|
Paul
Hansen
|
|
|
|
|
|
|
|
|
|
/s/
Geoffrey Harris
|
|
Director
|
|
May
17, 2021
|
Geoffrey
Harris
|
|
|
|
|
|
|
|
|
|
/s/
Joanna Horobin
|
|
Director
|
|
May
17, 2021
|
Joanna
Horobin
|
|
|
|
|
|
|
|
|
|
/s/
Howard McLeod
|
|
Director
|
|
May
17, 2021
|
Howard
McLeod
|
|
|
|
|
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Apr 2024 to May 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From May 2023 to May 2024